

ABUHB High Cost Drugs/NTF implementation Group

TERMS OF REFERENCE

The Health Board is under a statutory obligation to make treatments available to its patients for drugs endorsed by the Minister for Health in Wales following All Wales Medicines Strategy Group (AWMSG) advice and NICE technology appraisals. The relevant requirements are set out in the New Treatment Fund (NTF) as mandated in WHC 2017 (001).

The ABUHB high cost drugs group monitors the implementation of drug technologies within ABUHB for these drugs. It considers and makes recommendations on new implementation plans, infrastructure requirements and financial impact associated with the New Treatment Fund (NTF)

Core Functions of the group:

- To scrutinise and ratify the divisions' implementation forms for NICE and AWMSG approvals within the NTF
- To highlight to Medicines Management Programme Board implementation plans with a significant anticipated financial impact on drug budget or significant additional infrastructure requirements
- To co-ordinate and facilitate the annual horizon scanning process for high cost drugs
- To provide a link with All Wales Medicines Horizon Scanning Forecasting Group and disseminate information accordingly.
- Monitor ABUHB compliance with NTF and report this to MMPB.

Scope for additional functions of the group:

- To acknowledge and disseminate relevant Commercial Access Agreements and Managed Access Agreements available to ABUHB
- To approve any Early Access to Medicines schemes available to the Health Board.

Jurisdiction:

- Responsible for oversight of NTF implementation process.
- Responsible for highlighting and escalating implementation plans for NICE and AWMSG drug technology approvals with a drug financial impact or significant infrastructure requirements with NTF within the HB
- Responsible for co-ordinating and facilitating annual horizon scanning process

Roles and Responsibilities:

- Implementation plans for all NICE/AWMSG approvals via NTF will be submitted by directorate clinical leads and appraised by the group. This will allow directorates to examine the plans for impact on their services and plan accordingly.
- For new drugs with a significant financial impact or significant additional infrastructure requirements, the implementation plans submitted by relevant directorate will be forwarded to Medicines Management Programme Board for ratification.

- Contributing to Divisional financial forecasting for high cost drugs subject to NICE/AWMSG approval, including horizon scanning for new high impact drug treatments.
- Monitoring compliance with the terms and requirements of the Welsh New Treatment Fund, to ensure treatments are made available within 60 days of NICE Final appraisal recommendation or Welsh Ministerial endorsement of AWMSG drug technology recommendations. To highlight to Welsh Government when this will not be possible and apply for appropriate time extension.

Frequency

Meetings shall be held virtually monthly or as necessary to discharge its functions.

Accountability

ABUHB Medicines Management Programme Board

Chair

Clinical Director of Pharmacy

Membership

- Divisional Clinical representation as needed
- Finance representative.
- Secondary Care Prescribing Support Lead Pharmacist
- Clinical Effectiveness and Formulary Pharmacist
- Pharmacy Procurement Representation
- Risk Manager

Quorum and Governance

Chair (or deputy), representation from secondary care, finance representation.

Decisions will be made through consensus.

Financial or Personal Interests

Members should declare, in advance, financial, commercial or personal interests, whether pecuniary or otherwise, in any related matter that is the subject of consideration.